Atossa Therapeutics (ATOS) Set to Announce Earnings on March 25

Atossa Therapeutics (NASDAQ:ATOS) is set to release its quarterly earnings on Tuesday, March 25. Analysts are anticipating that the company will report earnings of ($0.06) per share for this quarter.

Atossa Therapeutics Stock Performance

As of Friday, NASDAQ:ATOS opened at $0.72. The company has a market capitalization of $90.01 million and a price-to-earnings ratio of -3.25. The stock has a beta of 1.20. Currently, the 50-day moving average stands at $0.81, while the two-hundred day moving average is $1.13. The stock experienced a 1-year low of $0.66 and a high of $2.31.

Institutional Investment in Atossa Therapeutics

Recently, an institutional investor increased its holdings in Atossa Therapeutics. Bank of America Corp DE raised its stake in the company by 51.3% during the fourth quarter. According to its latest SEC filing, the fund now owns 111,475 shares after adding 37,809 shares in the quarter. At the end of the recent reporting period, Bank of America Corp DE held 0.09% of Atossa Therapeutics, valued at $105,000. In total, institutional investors and hedge funds own 12.74% of the company's stock.

Analysts' Ratings on Atossa Therapeutics

Several equity analysts have expressed their opinions on Atossa's stock. HC Wainwright maintained a "buy" rating for the shares and set a target price of $7.00 in a report dated March 12. Similarly, Ascendiant Capital Markets increased their target price from $6.50 to $7.00, recommending it as a "buy" in their report from December 9.

Company Overview

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs in women's oncology, particularly breast cancer. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, currently undergoing Phase II clinical trials aimed at treating and preventing breast cancer.

Investment Insights

Before considering an investment in Atossa Therapeutics, it's advisable to review prominent research analysts' recommendations. Currently, while the company holds a Buy rating from several analysts, there are other stocks that analysts have identified as potentially better investment opportunities.

This article aims to provide accurate financial information sourced from multiple reports and analyses.

Earnings, Stocks, Biopharmaceuticals